Non ancora in reclutamento
Carcinoma epatocellulare+5
Non ancora in reclutamentoDB-1311 in combinazione con BNT327 o DB-1305 nei pazienti con tumori solidi avanzati o metastatici
Farmaco in studioSenza placebo
DB-1311 in combinazione con BNT327 o DB-1305 nei pazienti con tumori solidi avanzati o metastatici
Farmaco in studioSenza placebo
- Malattia:Carcinoma epatocellulareCarcinoma a cellule squamose del capo e del collo+4
- Principi attivi:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
Paesi:
Francia
Francia- Partecipanti:18–64 anni · 65 anni e più
- Principi attivi:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
- Promotore:Dualitybio Inc.
